TY - JOUR
T1 - Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis
AU - Chung, Jina
AU - Duffin, Kristina Callis
AU - Takeshita, Junko
AU - Shin, Daniel B.
AU - Krueger, Gerald G.
AU - Robertson, Andrew D.
AU - Troxel, Andrea B.
AU - Van Voorhees, Abby S.
AU - Edson-Heredia, Emily
AU - Gelfand, Joel M.
N1 - Funding Information:
This study was supported by grant RC1-AR058204 and K24-AR064310 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Gelfand), Dermatology Foundation Career Development Award (Dr Takeshita), T32-AR07465 from the National Institutes of Health (Mr Shin), and an unrestricted grant from Eli Lilly . The sponsors had no role in the design and conduct of the study, in the collection and management of the data, or in the preparation of the manuscript. An author from Eli Lilly participated in data analysis and interpretation, manuscript review, and decision to submit the manuscript. None of the other sponsors participated in data analysis/interpretation, review, or decision to submit the manuscript.
PY - 2014
Y1 - 2014
N2 - Background: The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown. Objective: We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis. Methods: We conducted a cross-sectional study of patients with plaque psoriasis (N = 1153) and palmoplantar psoriasis (N = 66) currently receiving systemic or light treatment for psoriasis. Results: Patients with palmoplantar psoriasisweremore likely to reportDermatology LifeQuality Index scores that correspond to at least a moderate impact on QoL (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.20-3.61); problemswithmobility (OR 1.98; 95% CI 1.10-3.58), self-care (OR 3.12; 95% CI 1.24-7.86), and usual activities (OR 2.47; 95% CI 1.44-4.22) on the European Quality of Life-5 Dimensions questionnaire; and heavy topical prescription use of at least twice daily in the precedingweek (OR 2.81; 95%CI 1.63-4.85) than thosewith plaque psoriasis. Limitations: Our assessment tools may not account for all dimensions of health-related QoL affected by palmoplantar disease, and these results may not be generalizable to patients with milder forms of psoriasis. Conclusion: Patients with palmoplantar psoriasis experience greater health-related QoL impairment and are more likely to report heavy use of topical prescriptions than those with moderate to severe plaque psoriasis.
AB - Background: The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown. Objective: We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis. Methods: We conducted a cross-sectional study of patients with plaque psoriasis (N = 1153) and palmoplantar psoriasis (N = 66) currently receiving systemic or light treatment for psoriasis. Results: Patients with palmoplantar psoriasisweremore likely to reportDermatology LifeQuality Index scores that correspond to at least a moderate impact on QoL (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.20-3.61); problemswithmobility (OR 1.98; 95% CI 1.10-3.58), self-care (OR 3.12; 95% CI 1.24-7.86), and usual activities (OR 2.47; 95% CI 1.44-4.22) on the European Quality of Life-5 Dimensions questionnaire; and heavy topical prescription use of at least twice daily in the precedingweek (OR 2.81; 95%CI 1.63-4.85) than thosewith plaque psoriasis. Limitations: Our assessment tools may not account for all dimensions of health-related QoL affected by palmoplantar disease, and these results may not be generalizable to patients with milder forms of psoriasis. Conclusion: Patients with palmoplantar psoriasis experience greater health-related QoL impairment and are more likely to report heavy use of topical prescriptions than those with moderate to severe plaque psoriasis.
KW - Epidemiology
KW - Health-related quality of life
KW - Palmoplantar psoriasis
KW - Patient-reported outcomes
KW - Plaque psoriasis
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=84910115973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910115973&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2014.04.063
DO - 10.1016/j.jaad.2014.04.063
M3 - Article
C2 - 24894455
AN - SCOPUS:84910115973
SN - 0190-9622
VL - 71
SP - 623
EP - 632
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -